High-Flow Nasal Cannula in Hypercapnic Respiratory Failure: A Systematic Review and Meta-Analysis

Yongkang Huang, Wei Lei, Wenyu Zhang, Jian-An Huang, Yongkang Huang, Wei Lei, Wenyu Zhang, Jian-An Huang

Abstract

Background: Although the efficacy and safety of high-flow nasal cannula (HFNC) in hypoxemic respiratory failure are widely recognized, it is yet unclear whether HFNC can effectively reduce the intubation rate and mortality in hypercapnic respiratory failure. We performed a systematic review and meta-analysis to assess the safety and efficiency of HFNC in these patients.

Methods: A systematic search of PubMed, Embase, and Cochrane Library (CENTRAL) was carried out. Two reviewers independently screened all references according to the inclusion criteria. We used the Cochrane risk-of-bias tool and the Newcastle-Ottawa Quality Assessment Scale to assess the quality of randomized controlled trials (RCTs) and cohort studies, respectively. Data from eligible trials were extracted for the meta-analysis.

Results: Eight studies with a total of 621 participants were included (six RCTs and two cohort studies). Our analysis showed that HFNC is noninferior to noninvasive ventilation (NIV) with respect to intubation rate in both RCTs (OR = 0.92, 95% CI: 0.45-1.88) and cohort studies (OR = 0.94, 95% CI: 0.55-1.62). Similarly, the analysis of cohort studies showed no difference in reducing mortality rates (OR = 0.96, 95% CI: 0.42-2.20). Based on RCTs, NIV seemed more effective in reducing mortality (OR = 1.33, 95% CI: 0.68-2.60), but the intertreatment difference was not statistically significant. Furthermore, no significant differences were found between HFNC and NIV relating to change of blood gas analysis or respiratory rate (MD = -0.75, 95% CI: -2.6 to 1.09). Likewise, no significant intergroup differences were found with regard to intensive care unit stay (SMD = -0.07, 95% CI: 0.26 to 0.11). Due to a physiological friendly interface and variation, HFNC showed a significant advantage over NIV in patients' comfort and complication of therapy.

Conclusion: Despite the limitations noted, HFNC may be an effective and safe alternative to prevent endotracheal intubation and mortality when NIV is unsuitable in mild-to-moderate hypercapnia. Further high-quality studies are needed to validate these findings.

Conflict of interest statement

The authors declare no conflicts of interest.

Copyright © 2020 Yongkang Huang et al.

Figures

Figure 1
Figure 1
Study flow.
Figure 2
Figure 2
Quality assessment of each eligible trial.
Figure 3
Figure 3
Intubation and mortality.
Figure 4
Figure 4
(a) Blood gas analysis. (b) Respiratory rate.
Figure 5
Figure 5
ICU stay.

References

    1. Cook D., Brower R., Cooper J., Brochard L., Vincent J.-L. Multicenter clinical research in adult critical care. Critical Care Medicine. 2002;30(7):1636–1643. doi: 10.1097/00003246-200207000-00039.
    1. Roussos C., Koutsoukou A. Respiratory failure. European Respiratory Journal. 2003;22(Supplement 47):3s–14s. doi: 10.1183/09031936.03.00038503.
    1. Esteban A., Anzueto A., Frutos F., et al. Characteristics and outcomes in adult patients receiving mechanical ventilation. Journal of the American Medical Association. 2002;287:345–355. doi: 10.1001/jama.287.3.345.
    1. Rochwerg B., Brochard L., Elliott M. W., et al. Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. European Respiratory Journal. 2017;50(2):p. 1602426. doi: 10.1183/13993003.02426-2016.
    1. Vagnarelli F., Marini M., Caretta G., et al. Noninvasive ventilation: general characteristics, indications, and review of the literature. Giornale italiano di cardiologia (Rome) 2017;18:496–504. doi: 10.1714/2700.27610.
    1. Bello G., De Pascale G., Antonelli M. Noninvasive ventilation. Clinics in Chest Medicine. 2016;37:711–721. doi: 10.1016/j.ccm.2016.07.011.
    1. Crimi C., Noto A., Princi P., Esquinas A., Nava S. A European survey of noninvasive ventilation practices. European Respiratory Journal. 2010;36:362–369. doi: 10.1183/09031936.00123509.
    1. Fleeman N., Mahon J., Bates V., et al. The clinical effectiveness and cost-effectiveness of heated humidified high-flow nasal cannula compared with usual care for preterm infants: a systematic review and economic evaluation. Health Technology Assessment. 2016;20:1–68. doi: 10.3310/hta20300.
    1. Nishimura M. High-flow nasal cannula oxygen therapy devices. Respiratory Care. 2019;64:735–742. doi: 10.4187/respcare.06718.
    1. Stefan M. S., Eckert P., Tiru B., et al. High flow nasal oxygen therapy utilization: 7-year experience at a community teaching hospital. Hospital Practice (1995) 2018;46:73–76. doi: 10.1080/21548331.2018.1438739.
    1. Ni Y., Luo J., Yu H., et al. Can high-flow nasal cannula reduce the rate of endotracheal intubation in adult patients with acute respiratory failure compared with conventional oxygen therapy and noninvasive positive pressure ventilation? Chest. 2017;151:764–775. doi: 10.1016/j.chest.2017.01.004.
    1. Higgins J. P. T., Green S. Cochrane Handbook for Systematic Reviews of Interventions. London, UK: The Cochrane Collaboration; 2008. .
    1. Wells G., Shea B., O’Connell D., et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. 2000. .
    1. Jing G., Li J., Hao D., et al. Comparison of high flow nasal cannula with noninvasive ventilation in chronic obstructive pulmonary disease patients with hypercapnia in preventing post-extubation respiratory failure: a pilot randomized controlled trial. Research and Nursing Health. 2019;42:217–225. doi: 10.1002/nur.21942.
    1. Cong L., Zhou L., Liu H., et al. Outcomes of high-flow nasal cannula versus non-invasive positive pressure ventilation for patients with acute exacerbations of chronic obstructive pulmonary disease. International Journal of Clinical and Experimental Medicine. 2019;12:10863–10867.
    1. Wang J. J., Jiang H. Y., Li Q. Randomized controlled study of HFNC and NPPV in the treatment of AECOPD combined with type II respiratory failure. Chinese Journal of Integrative Medicine. 2019:1–15. .
    1. Yu Z. H., Zhang R., Huang H., et al. Efficacy and safety of humidified high flow nasal cannula in chronic obstructive pulmonary disease complicated with type 2 respiratory failure patients after extubation: a randomized controlled trial. Academic Journal of Second Military Medical University. 2019;40:989–994. doi: 10.16781/j.0258-879x.2019.09.0989.
    1. Papachatzakis Y., Nikolaidis P. T., Kontogiannis S., et al. High-flow oxygen through nasal cannula vs. Non-invasive ventilation in hypercapnic respiratory failure: a randomized clinical trial. International Journal of Environmental Research and Public Health. 2020;17:1–8. doi: 10.3390/ijerph17165994.
    1. Tan D., Walline J. H., Ling B., et al. High-flow nasal cannula oxygen therapy versus non-invasive ventilation for chronic obstructive pulmonary disease patients after extubation: a multicenter, randomized controlled trial. Critical Care. 2020;24:p. 489. doi: 10.1186/s13054-020-03214-9.
    1. Sun J., Li Y., Ling B., et al. High flow nasal cannula oxygen therapy versus non-invasive ventilation for chronic obstructive pulmonary disease with acute-moderate hypercapnic respiratory failure: an observational cohort study. International Journal of Chronic Obstructive Pulmonary Disease. 2019;14:1229–1237. doi: 10.2147/COPD.S206567.
    1. Lee M. K., Choi J., Park B., et al. High flow nasal cannula oxygen therapy in acute-moderate hypercapnic respiratory failure. Clinical Respiratory Journal. 2018;12:2046–2056. doi: 10.1111/crj.12772.
    1. Pisani L., Betti S., Biglia C., et al. Effects of high-flow nasal cannula in patients with persistent hypercapnia after an acute COPD exacerbation: a prospective pilot study. BioMed Central Pulmonary Medicine. 2020;20:p. 12. doi: 10.1186/s12890-020-1048-7.
    1. Bräunlich J., Wirtz H. Nasal high-flow in acute hypercapnic exacerbation of COPD. International Journal of Chronic Obstructive Pulmonary Disease. 2018;13:3895–3897. doi: 10.2147/COPD.S185001.
    1. Pandya A., Criner G., So J., et al. Tolerance and safety of humidified high-flow nasal cannula oxygen therapy in patients hospitalized with an acute exacerbation of chronic obstructive pulmonary disease (COPD) American Journal of Respiratory and Critical Care Medicine. 2019;199 doi: 10.1164/ajrccm-conference.2019.199.1.
    1. Yang S., Zhang G., Liu Z., et al. Effect of high-flow nasal cannula oxygen therapy on diaphragmatic function in patients with acute exacerbation of chronic obstructive pulmonary disease: a prospective randomized controlled trial. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2019;31:551–555. doi: 10.3760/cma.j.issn.2095-4352.2019.05.006.
    1. Attaway A., Faress J. A., Jacono F. Safety and efficacy of oxygen delivery via high flow nasal cannula (HFNC) in patients with structural lung disease and chronic respiratory failur. American Journal of Respiratory and Critical Care. 2018;197
    1. Biselli P. J., Kirkness J. P., Grote L., et al. Nasal high-flow therapy reduces work of breathing compared with oxygen during sleep in COPD and smoking controls: a prospective observational study. Journal of Applied Physiology (1985) 2017;122:82–88. doi: 10.1152/japplphysiol.00279.2016.
    1. Mckinstry S., Pilcher J., Bardsley G., et al. Nasal high flow therapy and PtCO2 in stable COPD: a randomized controlled cross-over trial. Respirology. 2017;23(4):378–384. doi: 10.1111/resp.13185.
    1. Biselli P., Fricke K., Grote L., et al. Reductions in dead space ventilation with nasal high flow depend on physiological dead space volume: metabolic hood measurements during sleep in patients with COPD and controls. European Respiratory Journal. 2018;51 doi: 10.1183/13993003.02251-2017.
    1. Adams C. F., Geoghegan P. H., Spence C. J., et al. Modelling nasal high flow therapy effects on upper airway resistance and resistive work of breathing. Respiratory Physiology and Neurobiology. 2018;254:23–29. doi: 10.1016/j.resp.2018.03.014.
    1. Pisani L., Fasano L., Corcione N., et al. Change in pulmonary mechanics and the effect on breathing pattern of high flow oxygen therapy in stable hypercapnic COPD. Thorax. 2017;72:373–375. doi: 10.1136/thoraxjnl-2016-209673.
    1. Fraser J. F., Spooner A. J., Dunster K. R., et al. Nasal high flow oxygen therapy in patients with COPD reduces respiratory rate and tissue carbon dioxide while increasing tidal and end-expiratory lung volumes: a randomised crossover trial. Thorax. 2016;71:759–761. doi: 10.1136/thoraxjnl-2015-207962.
    1. Di Mussi R., Spadaro S., Stripoli T., et al. High-flow nasal cannula oxygen therapy decreases post-extubation neuroventilatory drive and work of breathing in patients with chronic obstructive pulmonary disease. Critical Care. 2018;22:p. 180. doi: 10.1186/s13054-018-2107-9.
    1. Corley A., Caruana L. R., Barnett A. G., et al. Oxygen delivery through high-flow nasal cannulae increase end-expiratory lung volume and reduce respiratory rate in post-cardiac surgical patients. British Journal of Anaesthesia. 2011;107:998–1004. doi: 10.1093/bja/aer265.
    1. Groves N., Tobin A. High flow nasal oxygen generates positive airway pressure in adult volunteers. Australian Critical Care. 2007;20:126–131. doi: 10.1016/j.aucc.2007.08.001.
    1. Bräunlich J., Mauersberger F., Wirtz H. Effectiveness of nasal high flow in hypercapnic COPD patients is flow and leakage dependent. BMC Pulmonary Medicine. 2018;18:p. 14. doi: 10.1186/s12890-018-0576-x.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe